Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 receptor (HER2), accounts for about 15–20% of breast cancers and represents the most aggressive breast cancer (BC) subtype1. Here, ERBB2 is linked to triple-negative breast carcinoma.